Comparative Clinical Analysis of Gastroenteropancreatic Neuroendocrine Carcinomas with Liver Metastasis and Primary Hepatic Neuroendocrine Carcinomas

Table 6

Univariate analysis of clinical features in gastroenteropancreatic neuroendocrine carcinoma patients with liver metastasis.

Variables	Survival status			values^a
	Death	Survival
Gender			0.027	0.869
Female	11	3
Male	14	6
Age (years)			0.708	0.400
≤50	7	2
>50	18	7
ALT (U/L)			1.231	0.267
≤40	19	8
>40	6	1
AST (U/L)			1.614	0.204
≤40	16	8
>40	9	1
HB (G/L)			0.740	0.390
≤110	4	3
>110	21	6
Albumin (G/L)			0.235	0.628
≤35	6	1
>35	19	8
ALP (U/L)			0.025	0.874
≤105	13	6
>105	12	3
GGT (U/L)			0.652	0.419
≤50	10	7
>50	15	2
Location in liver			0. 097	0.755
Left	3	7
Right	6	2
Unknown	16	0
Diameter			1.979	0.160
≤5 (cm)	12	5
>5 (cm)	7	0
Unknown	6	4
CA125 (μg/mL)			0.426	0.514
≤35	21	8
>35	3	1
Unknown	1	0
CA19-9 (μg/mL)			0.083	0.773
≤35	16	7
>35	8	2
Unknown	1	0
HbsAg			0.008	0.927
Positive	4	1
Negative	21	8
Treatment			10.955	0.001
Operation	12	5
Others	13	4
CK7			5.237	0.022
Positive	9	6
Negative	6	1
Unknown	10	2

ALT = alanine aminotransferase, AST = aspartate aminotransferase, HB = hemoglobin, ALP = alkaline phosphatase, GGT = γ-glutamyl transpeptidase, CA125 = carbohydrate antigen 125, CA19-9 = carbohydrate antigen 19-9, HbsAg = hepatitis B virus surface antigen. ^aKaplan–Meier survival curve and log-rank test. indicates .